vs
Side-by-side financial comparison of IDEAYA Biosciences, Inc. (IDYA) and STRATASYS LTD. (SSYS). Click either name above to swap in a different company.
IDEAYA Biosciences, Inc. is the larger business by last-quarter revenue ($207.8M vs $137.0M, roughly 1.5× STRATASYS LTD.). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs -40.6%, a 98.0% gap on every dollar of revenue. IDEAYA Biosciences, Inc. produced more free cash flow last quarter ($142.2M vs $2.5M).
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
Stratasys, Ltd. is an American-Israeli manufacturer of 3D printers, software, and materials for polymer additive manufacturing as well as 3D-printed parts on-demand. The company is incorporated in Israel. Engineers use Stratasys systems to model complex geometries in a wide range of polymer materials, including: ABS, polyphenylsulfone (PPSF), polycarbonate (PC), polyetherimide and Nylon 12.
IDYA vs SSYS — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $207.8M | $137.0M |
| Net Profit | $119.2M | $-55.6M |
| Gross Margin | — | 41.0% |
| Operating Margin | 52.2% | -16.6% |
| Net Margin | 57.4% | -40.6% |
| Revenue YoY | — | -2.2% |
| Net Profit YoY | 330.1% | -109.0% |
| EPS (diluted) | $1.33 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $207.8M | $137.0M | ||
| Q2 25 | — | $138.1M | ||
| Q1 25 | — | $136.0M | ||
| Q3 24 | $0 | $140.0M | ||
| Q2 24 | $0 | $138.0M | ||
| Q1 24 | $0 | $144.1M | ||
| Q3 23 | — | $162.1M | ||
| Q2 23 | — | $159.8M |
| Q3 25 | $119.2M | $-55.6M | ||
| Q2 25 | — | $-16.7M | ||
| Q1 25 | — | $-13.1M | ||
| Q3 24 | $-51.8M | $-26.6M | ||
| Q2 24 | $-52.8M | $-25.7M | ||
| Q1 24 | $-39.6M | $-26.0M | ||
| Q3 23 | — | $-47.3M | ||
| Q2 23 | — | $-38.6M |
| Q3 25 | — | 41.0% | ||
| Q2 25 | — | 43.1% | ||
| Q1 25 | — | 44.3% | ||
| Q3 24 | — | 44.8% | ||
| Q2 24 | — | 43.8% | ||
| Q1 24 | — | 44.4% | ||
| Q3 23 | — | 40.5% | ||
| Q2 23 | — | 41.5% |
| Q3 25 | 52.2% | -16.6% | ||
| Q2 25 | — | -12.0% | ||
| Q1 25 | — | -9.1% | ||
| Q3 24 | — | -18.2% | ||
| Q2 24 | — | -18.9% | ||
| Q1 24 | — | -17.0% | ||
| Q3 23 | — | -26.4% | ||
| Q2 23 | — | -21.1% |
| Q3 25 | 57.4% | -40.6% | ||
| Q2 25 | — | -12.1% | ||
| Q1 25 | — | -9.6% | ||
| Q3 24 | — | -19.0% | ||
| Q2 24 | — | -18.6% | ||
| Q1 24 | — | -18.0% | ||
| Q3 23 | — | -29.2% | ||
| Q2 23 | — | -24.2% |
| Q3 25 | $1.33 | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | $-0.60 | — | ||
| Q2 24 | $-0.68 | — | ||
| Q1 24 | $-0.53 | — | ||
| Q3 23 | — | $-0.68 | ||
| Q2 23 | — | $-0.56 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $786.9M | $71.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | $852.5M |
| Total Assets | $1.2B | $1.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $786.9M | $71.5M | ||
| Q2 25 | — | $71.1M | ||
| Q1 25 | — | $70.1M | ||
| Q3 24 | $920.0M | $64.0M | ||
| Q2 24 | $701.7M | $70.9M | ||
| Q1 24 | $698.8M | $91.1M | ||
| Q3 23 | — | $104.6M | ||
| Q2 23 | — | $144.4M |
| Q3 25 | $1.1B | $852.5M | ||
| Q2 25 | — | $902.4M | ||
| Q1 25 | — | $784.8M | ||
| Q3 24 | $1.2B | $831.8M | ||
| Q2 24 | $931.7M | $850.5M | ||
| Q1 24 | $935.3M | $866.1M | ||
| Q3 23 | — | $883.1M | ||
| Q2 23 | — | $923.2M |
| Q3 25 | $1.2B | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.0B | ||
| Q3 24 | $1.2B | $1.1B | ||
| Q2 24 | $973.7M | $1.1B | ||
| Q1 24 | $961.5M | $1.1B | ||
| Q3 23 | — | $1.2B | ||
| Q2 23 | — | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $142.2M | $6.9M |
| Free Cash FlowOCF − Capex | $142.2M | $2.5M |
| FCF MarginFCF / Revenue | 68.4% | 1.8% |
| Capex IntensityCapex / Revenue | 0.0% | 3.2% |
| Cash ConversionOCF / Net Profit | 1.19× | — |
| TTM Free Cash FlowTrailing 4 quarters | $13.5M | $-11.5M |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $142.2M | $6.9M | ||
| Q2 25 | — | $-1.1M | ||
| Q1 25 | — | $4.5M | ||
| Q3 24 | $-49.2M | $-4.5M | ||
| Q2 24 | $-32.9M | $-2.4M | ||
| Q1 24 | $-43.8M | $7.3M | ||
| Q3 23 | — | $-12.7M | ||
| Q2 23 | — | $-23.2M |
| Q3 25 | $142.2M | $2.5M | ||
| Q2 25 | — | $-8.4M | ||
| Q1 25 | — | $789.0K | ||
| Q3 24 | $-49.7M | $-6.3M | ||
| Q2 24 | $-33.9M | $-4.9M | ||
| Q1 24 | $-45.1M | $5.0M | ||
| Q3 23 | — | $-15.0M | ||
| Q2 23 | — | $-26.1M |
| Q3 25 | 68.4% | 1.8% | ||
| Q2 25 | — | -6.1% | ||
| Q1 25 | — | 0.6% | ||
| Q3 24 | — | -4.5% | ||
| Q2 24 | — | -3.6% | ||
| Q1 24 | — | 3.5% | ||
| Q3 23 | — | -9.3% | ||
| Q2 23 | — | -16.3% |
| Q3 25 | 0.0% | 3.2% | ||
| Q2 25 | — | 5.3% | ||
| Q1 25 | — | 2.8% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 1.8% | ||
| Q1 24 | — | 1.6% | ||
| Q3 23 | — | 1.4% | ||
| Q2 23 | — | 1.8% |
| Q3 25 | 1.19× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
